This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Endocrinology

Use of complemetary medicine in diabetes
Use of complementary medicine common in patients with diabetes
Risk of adverse cardiovascular events by adding newer diabetes drugs to insulin therapy
semaglutide weight loss
Significant weight loss achieved by semaglutide in obese patients without diabetes
bimagrumab and type 2 diabetes
Bimagrumab leads to significant fat loss in obese, type 2 diabetic patients


Popular articles

Aspirin use associated with improved survival but only for bladder and breast cancer
Metformin use in diabetes protective against COVID-19-related mortality
Low levels of alcohol intake linked to greater risk of atrial fibrillation
Bimagrumab leads to significant fat loss in obese, type 2 diabetic patients
Higher convalescent plasma antibody titre levels associated with lower risk of death in COVID-19




 
Hospital Healthcare Europe
 
LinkedIn Logo Footer  Twitter Logo Footer

Ⓒ Cogora 2021
Cogora Limited, 140 London Wall, London EC2Y 5DN, Registered in the United Kingdom. Reg. No. 2147432

Hospital Healthcare Europe
HOPE Logo Footer